A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS).
作者信息
Baughman Robert P, Tillinger Michael, Qin Yimin, Sweiss Nadera, Lower Elyse E
机构信息
University of Cincinnati Medical Center, Cincinnati, OH, USA.
Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA.
出版信息
Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):86-88. doi: 10.36141/svdld.v36i1.7748. Epub 2019 May 1.
Abstract
摘要
相似文献
1
A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS).评估结节病治疗反应的综合评分：结节病治疗评分（STS）。
Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):86-88. doi: 10.36141/svdld.v36i1.7748. Epub 2019 May 1.
2
Repository corticotropin for Chronic Pulmonary Sarcoidosis.用于慢性肺结节病的储存促肾上腺皮质激素
Lung. 2017 Jun;195(3):313-322. doi: 10.1007/s00408-017-9994-4. Epub 2017 Mar 28.
3
Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study.一项评估甲氨蝶呤与泼尼松作为肺结节病一线治疗方案有效性的随机对照试验设计：PREDMETH 研究。
BMC Pulm Med. 2020 Oct 19;20(1):271. doi: 10.1186/s12890-020-01290-9.
4
The management of sarcoidosis by the primary care physician.初级保健医生对结节病的管理。
Am J Med. 2007 May;120(5):403-7. doi: 10.1016/j.amjmed.2006.07.047.
5
Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.库欣促皮质素注射疗法治疗肺结节病的管理：德尔菲研究。
Eur Respir Rev. 2020 Mar 20;29(155). doi: 10.1183/16000617.0147-2019. Print 2020 Mar 31.
6
An Unusual Cause of a Solitary Lung Cavity.孤立性肺空洞的一种罕见病因。
Conn Med. 2016 Jan;80(1):25-8.
7
Predictors of objective cough frequency in pulmonary sarcoidosis.预测肺结节病患者的客观咳嗽频率的因素。
Eur Respir J. 2016 May;47(5):1461-71. doi: 10.1183/13993003.01369-2015. Epub 2016 Feb 4.
8
Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension.结节病相关肺动脉狭窄和肺动脉高压的介入治疗
Clin Respir J. 2017 Nov;11(6):906-914. doi: 10.1111/crj.12435. Epub 2016 Jan 6.
9
10
Clinical features of Sarcoidosis in Oman: A report from the Middle East region.阿曼结节病的临床特征：中东地区的一份报告。
Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):201-208.
引用本文的文献
1
Targeted proteomics in extracellular vesicles identifies biomarkers predictive for therapeutic response in sarcoidosis.细胞外囊泡中的靶向蛋白质组学可识别结节病治疗反应的预测生物标志物。
ERJ Open Res. 2025 Mar 3;11(2). doi: 10.1183/23120541.00672-2024. eCollection 2025 Mar.
2
Decreased serpin C1 in extracellular vesicles predicts response to methotrexate treatment in patients with pulmonary sarcoidosis.细胞外囊泡中丝氨酸蛋白酶抑制剂 C1 的减少可预测肺结节病患者对甲氨蝶呤治疗的反应。
Respir Res. 2024 Apr 16;25(1):166. doi: 10.1186/s12931-024-02809-y.
3
Pulmonary Function in Pulmonary Sarcoidosis.肺结节病的肺功能
J Clin Med. 2023 Oct 24;12(21):6701. doi: 10.3390/jcm12216701.
4
Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches.结节病：治疗药物试验及新治疗方法的最新进展
Front Med (Lausanne). 2022 Oct 12;9:991783. doi: 10.3389/fmed.2022.991783. eCollection 2022.
5
Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis.了解晚期症状性结节病患者对储存库促肾上腺皮质激素注射治疗反应的预测因素。
J Health Econ Outcomes Res. 2022 Apr 20;9(1):90-100. doi: 10.36469/jheor.2022.33295. eCollection 2022.
6
Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.注射用促肾上腺皮质激素治疗肺结节病：一项叙述性综述
Pulm Ther. 2022 Mar;8(1):43-55. doi: 10.1007/s41030-022-00181-0. Epub 2022 Feb 3.
本文引用的文献
1
Repository corticotropin for Chronic Pulmonary Sarcoidosis.用于慢性肺结节病的储存促肾上腺皮质激素
Lung. 2017 Jun;195(3):313-322. doi: 10.1007/s00408-017-9994-4. Epub 2017 Mar 28.
2
Sarcoidosis.结节病。
Lancet. 2014 Mar 29;383(9923):1155-67. doi: 10.1016/S0140-6736(13)60680-7. Epub 2013 Oct 1.
3
Endpoints for clinical trials of sarcoidosis.结节病临床试验的终点指标。
Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):90-8.
4
The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status.《国王结节病问卷的开发与验证：用于评估健康状况》。
Thorax. 2013 Jan;68(1):57-65. doi: 10.1136/thoraxjnl-2012-201962. Epub 2012 Oct 12.
5
Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.己酮可可碱在肺结节病中的激素节省作用。
Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):121-31.
6
The six-minute walk test in patients with pulmonary sarcoidosis.肺结节病患者的六分钟步行试验。
Ann Thorac Med. 2009 Apr;4(2):60-4. doi: 10.4103/1817-1737.49414.
7
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.英夫利昔单抗治疗慢性结节病合并肺部受累患者。
Am J Respir Crit Care Med. 2006 Oct 1;174(7):795-802. doi: 10.1164/rccm.200603-402OC. Epub 2006 Jul 13.
8
Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS).结节病疲劳程度的测量：疲劳评估量表（FAS）。
Br J Health Psychol. 2004 Sep;9(Pt 3):279-91. doi: 10.1348/1359107041557048.
9
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.英国胸科学会结节病研究：长期皮质类固醇治疗的效果
Thorax. 1996 Mar;51(3):238-47. doi: 10.1136/thx.51.3.238.
10
Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis.血清血管紧张素转换酶活性在结节病临床病程评估中的作用
Ann Intern Med. 1980 Mar;92(3):361-5. doi: 10.7326/0003-4819-92-3-361.
Zotero 插件